Glendon E. French III Sells 20,000 Shares of Pulmonx Co. (NASDAQ:LUNG) Stock

Pulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III sold 20,000 shares of the business’s stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $7.85, for a total value of $157,000.00. Following the completion of the transaction, the director now owns 991,974 shares in the company, valued at $7,786,995.90. This trade represents a 1.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Pulmonx Trading Up 0.9 %

Shares of LUNG opened at $7.77 on Friday. The stock has a fifty day moving average of $7.14 and a two-hundred day moving average of $6.96. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. The company has a market capitalization of $309.21 million, a PE ratio of -5.40 and a beta of 0.50. Pulmonx Co. has a fifty-two week low of $5.46 and a fifty-two week high of $10.01.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.12. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. The firm had revenue of $23.77 million during the quarter, compared to the consensus estimate of $22.29 million. As a group, analysts forecast that Pulmonx Co. will post -1.55 EPS for the current year.

Analyst Upgrades and Downgrades

LUNG has been the topic of several recent research reports. D. Boral Capital initiated coverage on Pulmonx in a research report on Monday, March 10th. They issued a “buy” rating and a $17.00 price target on the stock. Citigroup began coverage on Pulmonx in a report on Monday, March 10th. They issued a “buy” rating on the stock. Morgan Stanley began coverage on Pulmonx in a report on Monday, March 10th. They issued an “equal weight” rating on the stock. Jefferies Financial Group initiated coverage on Pulmonx in a report on Monday, March 10th. They issued a “buy” rating on the stock. Finally, Wells Fargo & Company decreased their price target on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Pulmonx presently has an average rating of “Moderate Buy” and a consensus price target of $13.36.

Hedge Funds Weigh In On Pulmonx

Several large investors have recently modified their holdings of the stock. Barclays PLC lifted its position in shares of Pulmonx by 1.8% during the third quarter. Barclays PLC now owns 94,109 shares of the company’s stock worth $780,000 after purchasing an additional 1,679 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Pulmonx by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 315,532 shares of the company’s stock worth $2,142,000 after acquiring an additional 2,363 shares during the period. Rhumbline Advisers raised its stake in Pulmonx by 4.9% during the fourth quarter. Rhumbline Advisers now owns 53,503 shares of the company’s stock worth $363,000 after acquiring an additional 2,488 shares during the period. American Century Companies Inc. raised its stake in Pulmonx by 8.8% during the fourth quarter. American Century Companies Inc. now owns 34,738 shares of the company’s stock worth $236,000 after acquiring an additional 2,810 shares during the period. Finally, 272 Capital LP acquired a new stake in Pulmonx during the third quarter worth about $25,000. Institutional investors own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.